CDEK
← All drugs Report issue

rimegepant

Trade name: Nurtec

Small moleculeapproved

Approved

Feb 27, 2020

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. It is taken by mouth to dissolve on or under the tongue. It works by blocking CGRP receptors. — Wikipedia

Clinical trial activity

36 trials · 14 clinical orgs · 2 marketing orgs

Phase 1
1
Phase 2
20
Phase 3
17
Phase 4
9

Earliest trial started Oct 1, 2011 (NCT01430442)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2017

    Biohaven Pharmaceuticals Inc. — Earliest Phase 3 Sponsor(trial)

2020s

  1. Feb 27, 2020

    Pfizer — Earliest FDA Approval

  2. Feb 27, 2020

    Biohaven Pharmaceuticals Inc. — Marketing Organization

  3. Feb 27, 2020

    Pfizer — Marketing Organization

  4. Feb 27, 2020

    Pfizer — NDA Secondary Org

  5. Feb 27, 2020

    Pfizer — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewFeb 27, 2020

Chemistry & pharmacology

Loading structure…

SMILES

N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
Mol. weight
534.57 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate
  • bms-927711
  • bms-927711
  • bms-927711
  • bms-927711
  • rimegepant
  • rimegepant
  • rimegepant

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07301008Phase 4Sep 9, 2025Georgetown University, Pfizer
NCT06999252Phase 2Jul 1, 2025Fudan University
NCT06985342Phase 4Jun 5, 2025Icahn School of Medicine at Mount Sinai, Pfizer
NCT06992674Phase 2Jun 1, 2025Zhejiang University
NCT06748664Phase 2Apr 1, 2025Zhejiang University
NCT06641466Phase 3Dec 24, 2024Pfizer
NCT06616194Phase 3Dec 1, 2024Pfizer
NCT06221111Phase 2Jun 6, 2024Mayo Clinic, Pfizer
NCT05810038Phase 3May 15, 2023Pfizer
NCT05518123Phase 4Nov 7, 2022Pfizer
NCT05509400Phase 4Oct 18, 2022Pfizer
NCT05264714Phase 2Sep 7, 2022Mayo Clinic
NCT05399459Phase 2/Phase 3 (Phase 3)Aug 9, 2022Pfizer
NCT05399485Phase 3Aug 9, 2022Pfizer
NCT05371652Phase 3May 19, 2022Biohaven Pharmaceuticals Inc., Bioshin (Shanghai) Consulting Services Co., Ltd
NCT05262517Phase 2/Phase 3 (Phase 3)May 5, 2022Pfizer
NCT05211154Phase 4May 5, 2022University of Copenhagen
NCT05207865Phase 4Mar 15, 2022Biohaven Pharmaceuticals Inc.
NCT05217927Phase 4Mar 4, 2022Biohaven Pharmaceuticals Inc.
NCT05248997Phase 2/Phase 3 (Phase 3)Feb 17, 2022Pfizer
Showing 20 of 36 trials
Page 1 / 2

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Biohaven Pharmaceuticals Inc.For profit151442017
PfizerFor profit12932022
Bristol-Myers SquibbFor profit2222011
Mayo ClinicAcademic/Hospital2212022
Zhejiang UniversityAcademic/Hospital2212025
BioShin LimitedFor profit1012020
Bioshin (Shanghai) Consulting Services Co., LtdFor profit1012022
Cornell UniversityAcademic/Hospital1112020
Eli LillyFor profit1112021
Fudan UniversityAcademic/Hospital1112025
Georgetown UniversityAcademic/Hospital1112025
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112025
Maimonides Medical CenterAcademic/Hospital1112021
University of CopenhagenAcademic/Hospital1112022
14 organizations
Page 1 / 1

Marketing (5)

OrganizationOrg typeRelationshipDate
Biohaven Pharmaceuticals Inc.For profitMKTGFeb 27, 2020
Biohaven Pharmaceuticals Inc.For profitMKTGFeb 27, 2020
PfizerFor profitMKTGFeb 27, 2020
PfizerFor profitNDA2Feb 27, 2020
PfizerFor profitNDAFeb 27, 2020